Ocugen

Yahoo Finance • 11 hours ago

Ocugen to Present at Industry and Investor Conferences in October 2025

MALVERN, Pa., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that executive leadership will present a... Full story

Yahoo Finance • 18 days ago

Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

Upfront fees and near-term development milestone payments totaling up to $7.5 millionPotential sales milestones of $180 million or more in first 10 years of commercializationRoyalties equaling 25% of net salesOcugen to manufacture and supp... Full story

Yahoo Finance • last month

Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025

MALVERN, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, Ch... Full story

Yahoo Finance • 2 months ago

Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease

MALVERN, Pa., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Committee for Medicinal Products fo... Full story

Yahoo Finance • 2 months ago

Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants

MALVERN, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the closing of its previously announced regi... Full story

Yahoo Finance • 2 months ago

Ocugen launches $20 million direct offering of common stock, warrants

* Ocugen (NASDAQ:OCGN [https://seekingalpha.com/symbol/OCGN]) has entered into a securities purchase agreement with Janus Henderson Investors to purchase 20M shares of common stock and warrants for gross proceeds of $20 million * The c... Full story

Yahoo Finance • 2 months ago

Ocugen raises $20 million in registered direct offering

MALVERN, Pa. - Ocugen, Inc. (NASDAQ:OCGN), a biotechnology company focused on gene therapies for blindness diseases, announced today it has secured a $20 million investment through a registered direct offering with Janus Henderson Investor... Full story

Yahoo Finance • 2 months ago

Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants

MALVERN, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it has entered into a securities purcha... Full story

Yahoo Finance • 2 months ago

MannKind Non-GAAP EPS of $0.05 misses by $0.03, revenue of $76.53M misses by $2.25M

* MannKind press release [https://seekingalpha.com/pr/20190756-mannkind-corporation-reports-second-quarter-2025-financial-results-and-provides-business] (NASDAQ:MNKD [https://seekingalpha.com/symbol/MNKD]): Q2 Non-GAAP EPS of $0.05 misse... Full story

Yahoo Finance • 2 months ago

Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team

MALVERN, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced updates to its Retina Scientific Advisory Bo... Full story

Yahoo Finance • 3 months ago

Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST—Novel Modifier Gene Therapy Candidate for Stargardt Disease

MALVERN, Pa., July 18, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the first patient has been dosed in its... Full story

Yahoo Finance • 3 months ago

Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results

MALVERN, Pa., July 17, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live... Full story

Yahoo Finance • 3 months ago

Ocugen receives additional 180-day extension from Nasdaq to meet $1 minimum bid

Ocugen, Inc. (NASDAQ:OCGN), a $269.25 million market cap biotechnology company currently trading at $0.93, announced Tuesday it has received an additional 180 calendar days from the Nasdaq Stock Market to regain compliance with the minimum... Full story

Yahoo Finance • 3 months ago

Carisma Therapeutics, OrthoCellix enter definitive merger agreement

Carisma Therapeutics (CARM) and OrthoCellix, a wholly-owned subsidiary of Ocugen (OCGN), announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will fo... Full story

Yahoo Finance • 3 months ago

Ocugen stock steady as H.C. Wainwright reiterates buy rating

Investing.com - H.C. Wainwright reiterated its buy rating and $7.00 price target on Ocugen, Inc. (NASDAQ:OCGN) on Monday, following the company’s announcement about its regenerative medicine asset. Want deeper insights into OCGN’s valuatio... Full story

Yahoo Finance • 3 months ago

Carisma and OrthoCellix to merge for knee cartilage repair therapy

PHILADELPHIA/MALVERN - Carisma Therapeutics Inc. (NASDAQ:CARM), currently trading at $0.44 with a market capitalization of $18.4 million and rated ’FAIR’ by InvestingPro’s Financial Health Score, and OrthoCellix, a wholly-owned subsidiary... Full story

Yahoo Finance • 3 months ago

Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases

Proposed reverse merger with OrthoCellix, a wholly-owned subsidiary of Ocugen, to create Nasdaq-listed, late clinical-stage regenerative cell therapy company with a first-in-class technology platform, focused on orthopedic diseasesOrthoCel... Full story

Yahoo Finance • 4 months ago

Ocugen Says FDA Cleared IND Amendment To Initiate Phase 2/3 Study Of OCU410ST In Stargardt Disease

(RTTNews) - Ocugen, Inc. (OCGN), Monday said that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) amendment to initiate a Phase 2/3 pivotal confirmatory study of OCU410ST, the company's gene thera... Full story

Yahoo Finance • 4 months ago

Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease

MALVERN, Pa., June 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the U.S. Food and Drug Administration (... Full story

Yahoo Finance • 4 months ago

Ocugen To Present at BIO International Convention 2025

MALVERN, Pa., June 11, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present at the 2025 BI... Full story